Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • 14 March 2014

    GSK marketed products Mekinist in combination with Tafinlar received FDA nod for Advanced Melanoma

    FDA approved combination therapy of Mekinist (trametinib) and Tafinlar (dabrafenib) for treatment of advanced melanoma that is unresectable or metastatic. In May 2013, FDA had already approved both drugs as single agents to treat patients with unresectable or metastatic melanoma, skin cancer.

  • 14 March 2014
    Aha Moment : NSAIDs could be used to fight drug resistant bacterias

    New serendipitous discovery which may open a new concept of resisting bacteria from growing in body. Associate professor Aaron Oakley and his team reported that non-steroidal anti-inflammatory drugs (NSAIDs) are exhibit some antibacterial property and acting on DNA replication of bacteria.

  • 13 March 2014
    Similarity in damage due to Alzheimer's Disease in Twins

    Researchers found that twin pairs had similar progressions of Alzheimer’s Disease (AD) and dementia prior to death and even they also had similar combinations of pathogenesis in two or more unconnected areas of damage to the brain. This unique study was conducted by international team of researchers led by USC psychologist Margaret Gatz.

  • 13 March 2014
    Novartis's Jakavi ® shows positive Phase III results in Polycythemia Vera

    Novartis announced that Jakavi ® (ruxolitinib) showed positive reponse in compare to present therpies for Polycythemia Vera, a rare and incurable blood cancer with increase number of erythrocytes production. In phase III trial, Jakavi ® succeed to maintain hematocrit control, erythrocytes volume, without the need of phlebotomy and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea.

  • 13 March 2014
    Gujarat plant of Sun Pharma hit by import ban from FDA

    Karkhadi (Gujarat) based plant of Sun Pharmaceuticals imposed ban by USFDA. This ban is applied on import of all drug products from this plant. This detention was carried out without physical examination of drugs because company failed to met good manufacturing practices rules, as per FDA website on Wednesday.

  • 12 March 2014
    FDA issued warning letter against Indian based Canton Laboratories upon quality issues

    During  their last investigation in April 2013 at Canton Laboratories- Vadodara,  U.S. food and Drug Administration (FDA) identified significant deviations from current good manufacturing practice (CGMP) for the manufacture of active pharmaceutical ingredients (APIs) and in view of it, FDA issued a warning letter.

    [adsense:336x280:8701650588]

  • 12 March 2014
    Cefaly gets FDA approval for marketing - First medical device approved to prevent migraine

    U.S. Food and Drug Administration allowed marketing of the first device, Cefaly-manufactured by STX-Med in Belgium, as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain.

  • 12 March 2014
    Now blood test can predict Alzheimer’s and Mild Dementia

    A blood test that can predict with 90 percent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease (AD) within three years has been discovered and validated by researchers at Georgetown and six other institutions. They discovered and validated 10 lipid biomarkers out of which 2 are strongly associated with neuropathology of AD.

  • 11 March 2014
    New Class of Antibiotics found for treatment of Superbug - MRSA and other drug-resistant bacterias

    A team of University of Notre Dame researchers led by Mayland Chang and Shahriar Mobashery have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria that threaten public health.

  • 11 March 2014
    Synthetic Biologics announces issuance of US Patent for the use of Oral Estriol -Trimesta™ for treatment of Multiple Sclerosis & other Autoimmune Diseases

    Synthetic Biologics, Inc., a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA).

Subscribe to Pharma News